[go: up one dir, main page]

NO331017B1 - Glukan, adjuvanssammensetning omfattende glukanet samt anvendelse av glukanet for fremstilling av en mukosal administrerbar adjuvanssammensetning. - Google Patents

Glukan, adjuvanssammensetning omfattende glukanet samt anvendelse av glukanet for fremstilling av en mukosal administrerbar adjuvanssammensetning.

Info

Publication number
NO331017B1
NO331017B1 NO20023935A NO20023935A NO331017B1 NO 331017 B1 NO331017 B1 NO 331017B1 NO 20023935 A NO20023935 A NO 20023935A NO 20023935 A NO20023935 A NO 20023935A NO 331017 B1 NO331017 B1 NO 331017B1
Authority
NO
Norway
Prior art keywords
glucan
adjuvant composition
preparation
well
mucosally administrable
Prior art date
Application number
NO20023935A
Other languages
English (en)
Other versions
NO20023935D0 (no
NO20023935L (no
Inventor
Bjorn Haneberg
Jan Raa
Aud Kathrine Herland Berstad
Hilde Bakke
Inger Lise Haugen
Johan Holst
Liba Janakova
Gro Ellen Korsvold
Fredrik Oftung
Original Assignee
Biotec Pharmacon Asa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotec Pharmacon Asa filed Critical Biotec Pharmacon Asa
Publication of NO20023935D0 publication Critical patent/NO20023935D0/no
Publication of NO20023935L publication Critical patent/NO20023935L/no
Publication of NO331017B1 publication Critical patent/NO331017B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20023935A 2000-02-23 2002-08-19 Glukan, adjuvanssammensetning omfattende glukanet samt anvendelse av glukanet for fremstilling av en mukosal administrerbar adjuvanssammensetning. NO331017B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/511,582 US20020009463A1 (en) 2000-02-23 2000-02-23 Novel, non-antigenic, mucosal adjuvant formulation which enhances the effects of substances, including vaccine antigens, in contact with mucosal body surfaces
PCT/IB2001/000144 WO2001062283A2 (en) 2000-02-23 2001-02-02 Mucosal adjuvant formulation

Publications (3)

Publication Number Publication Date
NO20023935D0 NO20023935D0 (no) 2002-08-19
NO20023935L NO20023935L (no) 2002-10-15
NO331017B1 true NO331017B1 (no) 2011-09-12

Family

ID=24035524

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20023935A NO331017B1 (no) 2000-02-23 2002-08-19 Glukan, adjuvanssammensetning omfattende glukanet samt anvendelse av glukanet for fremstilling av en mukosal administrerbar adjuvanssammensetning.

Country Status (10)

Country Link
US (3) US20020009463A1 (no)
EP (1) EP1259259B1 (no)
JP (2) JP4947506B2 (no)
CN (1) CN1404399B (no)
AT (1) ATE511855T1 (no)
AU (1) AU771205B2 (no)
DK (1) DK1259259T3 (no)
ES (1) ES2369550T3 (no)
NO (1) NO331017B1 (no)
WO (1) WO2001062283A2 (no)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7507724B2 (en) 2001-01-16 2009-03-24 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
JPWO2003039567A1 (ja) * 2001-11-06 2005-02-24 株式会社オリエントキャンサーセラピー 抗癌組成物
KR20050044523A (ko) * 2001-11-19 2005-05-12 벡톤 디킨슨 앤드 컴퍼니 입자 형태의 약제학적 조성물
CA2485999C (en) * 2002-05-14 2015-02-17 Chiron Srl Mucosal combination vaccines for bacterial meningitis
US20090068207A1 (en) * 2005-04-15 2009-03-12 Vascular Biogenics Ltd. Compositions Containing Beta 2-Glycoprotein I-Derived Peptides for the Prevention and/or Treatment of Vascular Disease
US8323644B2 (en) 2006-01-17 2012-12-04 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US11316688B2 (en) 2006-12-29 2022-04-26 Kip Prod P1 Lp Multi-services application gateway and system employing the same
US20170344703A1 (en) 2006-12-29 2017-11-30 Kip Prod P1 Lp Multi-services application gateway and system employing the same
WO2008085206A2 (en) 2006-12-29 2008-07-17 Prodea Systems, Inc. Subscription management of applications and services provided through user premises gateway devices
US9602880B2 (en) 2006-12-29 2017-03-21 Kip Prod P1 Lp Display inserts, overlays, and graphical user interfaces for multimedia systems
US9569587B2 (en) 2006-12-29 2017-02-14 Kip Prod Pi Lp Multi-services application gateway and system employing the same
US11783925B2 (en) 2006-12-29 2023-10-10 Kip Prod P1 Lp Multi-services application gateway and system employing the same
CN101244267B (zh) * 2007-02-12 2011-12-21 复旦大学 一种增强微生物疫苗免疫原性的免疫制剂
US20100322923A1 (en) * 2007-02-21 2010-12-23 Biotec Pharmacon Asa Medical Uses of Glucans
JP5272129B2 (ja) * 2007-04-25 2013-08-28 幸仁 秋山 インフルエンザウイルスの不活化抗原に対するアジュバント、及び分泌型ＩｇＡ抗体誘導剤
TWI496578B (zh) * 2009-10-08 2015-08-21 Aureo Co Ltd 流感病毒感染症的治療劑
WO2011142488A1 (ko) * 2010-05-12 2011-11-17 주식회사 글루칸 관절염 치료제
JP5242855B2 (ja) * 2010-07-29 2013-07-24 国立大学法人北海道大学 免疫アジュバント
EP2694030A2 (en) 2011-03-04 2014-02-12 Sana Pharma AS Cosmetic formulations
EP2825500B1 (en) 2012-03-13 2016-01-06 Becton Dickinson France Method of manufacture for a miniaturized drug delivery device
EP3784250B1 (en) * 2018-04-24 2025-01-01 Memorial Sloan Kettering Cancer Center Methods of enhancing immunogenicity of poorly immunogenic antigen-specific vaccines using oral yeast beta-glucans
CN111420044B (zh) * 2020-05-11 2021-04-09 中逸安科生物技术股份有限公司 一种四价流感病毒亚单位疫苗及其制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3071750D1 (en) * 1979-07-04 1986-10-16 Kureha Chemical Ind Co Ltd Nasal preparations, process for making same and their use
DE3019614A1 (de) * 1980-05-22 1981-12-03 Sankyo Co., Ltd., Tokyo Hydrolysiertes polysaccharid
EP0045718A3 (de) * 1980-07-25 1983-01-19 Ciba-Geigy Ag Nasalpräparate und Verfahren zu deren Herstellung
US4857318A (en) * 1983-11-07 1989-08-15 Syntex (U.S.A.) Inc. Bordetella bronchiseptica pilus subunit protein vaccine effective against bordetella pertussis
US4810646A (en) * 1984-11-28 1989-03-07 Massachusetts Institute Of Technology Glucan compositions and process for preparation thereof
CA1330303C (en) * 1989-02-20 1994-06-21 Libor Henry Nikl Composition and process to enhance the efficacy of a fish vaccine
US5032401A (en) * 1989-06-15 1991-07-16 Alpha Beta Technology Glucan drug delivery system and adjuvant
US5488040A (en) * 1989-09-08 1996-01-30 Alpha-Beta Technology, Inc. Use of neutral soluble glucan preparations to stimulate platelet production
US5223491A (en) * 1989-11-09 1993-06-29 Donzis Byron A Method for revitalizing skin by applying topically water insoluble glucan
CA2040374C (en) * 1990-07-06 1998-06-16 Gunnar Rorstad Process for enhancing the resistance of aquatic animals to disease
JP3522772B2 (ja) * 1991-05-21 2004-04-26 台糖株式会社 ワクチンの免疫効果増強剤
NO300692B1 (no) * 1994-04-29 1997-07-07 Biotec Mackzymal As Solubilisert forgrenet ß-1,3-glukan og anvendelse derav samt anvendelse av usolubilisert forgrenet ß-1,3-glukan
AUPN166195A0 (en) * 1995-03-13 1995-04-06 Norvet Research Pty Limited Process for glucan extraction
US5785975A (en) * 1995-06-26 1998-07-28 Research Triangle Pharmaceuticals Adjuvant compositions and vaccine formulations comprising same
EP1089751A4 (en) * 1998-06-23 2001-07-25 Univ Leland Stanford Junior Adjuvant therapy

Also Published As

Publication number Publication date
AU4094301A (en) 2001-09-03
US20120014991A1 (en) 2012-01-19
AU771205B2 (en) 2004-03-18
EP1259259B1 (en) 2011-06-08
JP2011190278A (ja) 2011-09-29
ATE511855T1 (de) 2011-06-15
EP1259259A2 (en) 2002-11-27
NO20023935D0 (no) 2002-08-19
CN1404399A (zh) 2003-03-19
US20020009463A1 (en) 2002-01-24
WO2001062283A3 (en) 2002-02-14
JP2003523401A (ja) 2003-08-05
NO20023935L (no) 2002-10-15
CN1404399B (zh) 2012-04-04
US20030104010A1 (en) 2003-06-05
JP4947506B2 (ja) 2012-06-06
ES2369550T3 (es) 2011-12-01
DK1259259T3 (da) 2011-08-01
WO2001062283A2 (en) 2001-08-30

Similar Documents

Publication Publication Date Title
NO331017B1 (no) Glukan, adjuvanssammensetning omfattende glukanet samt anvendelse av glukanet for fremstilling av en mukosal administrerbar adjuvanssammensetning.
WO2001060402A3 (en) Proteosome influenza vaccine
IS4518A (is) Nýtt lyfjaform fyrir bóluefni
DE60039198D1 (de) Adjuvanszusammensetzungen zur Erhöhung der Immunantwort bezüglich Polynukleotid-basierenden Impfstoffen
NO20015073L (no) Vaksiner
UY26555A1 (es) Composición farmacéutica para modulación inmunológica y preparación de vacunas
DE60012042D1 (de) Entepneumovirus und entsprechendes impfstoff
ES2186809T3 (es) Composiciones de vacunas para administracion intranasal, comprendiendo chitosana y su uso.
WO2002028422A3 (en) Split enveloped virus preparation for intranasal delivery
DK1265633T3 (da) Vaccineadjuvans
AU2151902A (en) Pharmaceutical compositions enhancing the immunogenicity of poorly immunogenic antigens
AU2002221519A1 (en) Pharmaceutical compositions enhancing the immunogenicity of poorly immunogenic antigens
WO2003066094A3 (en) Hepatitis b vaccines
AU2001284354A1 (en) Immunological adjuvant compounds, compositions, and methods of use thereof
GB2444676A (en) Adjuvanted vaccine
WO2000006198A3 (en) Adjuvant comprising pulmonary surfactant
ATE353226T1 (de) Adjuvanszusammensetzung enthaltend fha oder ein fha-fragment in freier form
DK1401492T3 (da) LTB4 som vaccineadjuvans
WO2001062240A3 (fr) Utilisation d'un detergent de type zwittergent pour la preparation d'une composition pharmaceutique destinee a etre administree par voie nasale
WO2002072622A3 (en) Vaccine antigens against infection by chlamydia trachomatis
HUP0002033A2 (hu) A csirke parvovírus által okozott betegségek elleni oltóanyag
EP1721618A3 (en) Proteosome influenza vaccine composition
WO2004106365A3 (en) Modulatory peptide motifs for inducing th1 or th2 immune response

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees